CEO, PSS Segment Weitzman Deborah covered exercise/tax liability with 632 shares, decreasing direct ownership by 1% to 49,129 units (SEC Form 4)

$CAH
Other Pharmaceuticals
Health Care
Get the next $CAH alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WEITZMAN DEBORAH

(Last) (First) (Middle)
7000 CARDINAL PLACE

(Street)
DUBLIN OH 43017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CARDINAL HEALTH INC [ CAH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, PSS Segment
3. Date of Earliest Transaction (Month/Day/Year)
12/02/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 12/02/2024 F(1) 632 D $122.24(2) 49,129 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with restricted share units.
2. Reflects closing price on prior business day.
Remarks:
/s/ James E. Barnett, Attorney-in-fact 12/03/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CAH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CAH

DatePrice TargetRatingAnalyst
2/5/2025$140.00 → $150.00Hold → Buy
Jefferies
1/8/2025$130.00 → $144.00Hold → Buy
TD Cowen
1/7/2025$140.00In-line → Outperform
Evercore ISI
1/6/2025$132.00 → $145.00Neutral → Buy
BofA Securities
12/13/2024$101.00 → $127.00Underweight → Equal Weight
Wells Fargo
12/4/2024$139.00Outperform
Mizuho
2/26/2024$125.00Outperform
Leerink Partners
2/9/2024Hold → Buy
Argus
More analyst ratings

$CAH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2025 on May 1

    DUBLIN, Ohio, March 25, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) plans to release third-quarter financial results for its fiscal year 2025 on May 1, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal Health Cardinal Hea

    $CAH
    Other Pharmaceuticals
    Health Care
  • Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    $CAH
    Other Pharmaceuticals
    Health Care
  • Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nucle

    $CAH
    Other Pharmaceuticals
    Health Care

$CAH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CAH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CAH
SEC Filings

See more

$CAH
Leadership Updates

Live Leadership Updates

See more
  • Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    $CAH
    Other Pharmaceuticals
    Health Care
  • RPM Announces Appointment of Three New Board Members

    RPM International Inc. (NYSE:RPM) today announced the appointment of three individuals, Craig S. Morford, Christopher L. Mapes and Julie A. Beck, to its board of directors. These appointments reflect RPM's ongoing commitment to expanding the expertise, diversity and leadership capabilities of its board as the company continues to drive long-term growth and shareholder value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113146614/en/Christopher L. Mapes (Photo: Business Wire) The appointments of Mr. Morford and Mr. Mapes are effective immediately, and Ms. Beck's term is set to commence on April 7, 2025. With these additions,

    $AOS
    $CAH
    $LECO
    $NDSN
    Consumer Electronics/Appliances
    Consumer Discretionary
    Other Pharmaceuticals
    Health Care
  • Bob Azelby to join Cardinal Health Board of Directors

    DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmac

    $CAH
    Other Pharmaceuticals
    Health Care

$CAH
Financials

Live finance-specific insights

See more
  • Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nucle

    $CAH
    Other Pharmaceuticals
    Health Care
  • Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

    Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expirationGAAP1 operating earnings were $549 million; GAAP diluted EPS was $1.65Non-GAAP operating earnings increased 9% to $635 million, driven by the Pharmaceutical and Specialty Solutions segment; non-GAAP diluted EPS increased 2% to $1.93Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.85 to $8.00, from $7.75 to $7.90Company announces the completion of its acquisition of 73% ownership of GI AllianceDUBLIN, Ohio, Jan. 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported second quarter fiscal year 2025 revenues of $55.3 billion, a decrea

    $CAH
    Other Pharmaceuticals
    Health Care
  • Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 5, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2025 to shareholders of record at the close of business on January 2, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    $CAH
    Other Pharmaceuticals
    Health Care

$CAH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more